All News

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.

Fewer than 40% of people have ever had a HIV test, and less than 30% of people in the United States most at risk of acquiring HIV were tested in the past year.

First-line treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) demonstrated overall and progression-free long-term survival benefits in patients with BRAF-mutation positive melanoma.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

In a prepared statement, Pharmacy Quality Alliance (PQA) Chief Executive Officer Laura Cranston, RPh, said the organization applauds the initiatives outlined in “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.”

The advisory board voted unanimously on Wednesday to recommend HPV vaccines for people through age 26.

Officials with the FDA have approved Dova Pharmaceuticals’ supplemental New Drug Application (sNDA) for expanding the use of avatrombopag (Doptelet).

Avatrombopag was previously approved by the agency for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.

Data from a phase 2 study demonstrated that topical ruxolitinib cream significantly improved repigmentation of facial lesions in adults with vitiligo.

Top news of the day from across the health care landscape.

CRSwNP often occurs with severe asthma and requires systemic steroids or nasal surgery, the current standard of care.

Dupilumab (Dupixent) is the first biologic medicine approved for inadequately controlled chronic rhinosinusitis with nasal polyposis.

To date, the Ohio audit is the first comprehensive review of PBM practices and incorporated 39 million drug transactions, the authors said.

The drug is earned the designation for reducing the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

The recently-finalized CMS drug pricing rule excluded direct and indirect remuneration fee reform.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

Removal of the offending agent(s) is the first step in treatment for acquired methemoglobinemia.

The letters request actions to correct violations cited by the agency.

Due to physician shortages, pharmacists represent a new avenue to increase accessibility to antivirals.

Announced by both companies today, the new combined company will consist of franchises across immunology, hematologic oncology, medical aesthetics, neuroscience, women’s health, eye care, and virology.

An independent review of pharmacy benefit managers (PBMs) in Ohio indicates that PBM pricing practices likely contribute to rising health care costs.

The approved product is therapeutically equivalent to Genentech’s Tamiflu I Capsules, 30 mg, 45 mg, and 75 mg.

A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.